Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

ons.

"The decision to trigger data cutoff and analysis based on trial duration relies on our level of confidence that the assumptions in the sample size calculations are appropriate; the most significant of which is the behavior of the control group. The guidance from the independent DMB combined with simulations we have performed based on the long-term follow-up from our Phase 2 trial gives us confidence that the timing of this analysis will provide adequate patient follow-up needed to retain the pre-specified statistical power of the trial. It is important to note that the DMB assessment was performed in a manner which ensured blinding and the integrity of this pivotal Phase 3 trial."

Third Quarter 2007 Financial Review

Favrille also reported its financial results for the third quarter of 2007. For the three and nine months ended September 30, 2007, the Company reported net losses of $12.3 million, or $0.37 per share, and $35.2 million, or $1.10 per share, respectively, compared to a net loss of $9.6 million, or $0.33 per share, and $30.3 million, or $1.13 per share, for the same periods in 2006.

Research and development expense was approximately $9.5 million and $27.1 million for the three and nine months ended September 30, 2007, respectively, compared to approximately $7.5 million and $23.4 million for the same periods in 2006. The increases were primarily due to additional expenses for personnel and stock-based compensation and increases in validation, rent and operating costs, supplies and depreciation related to the commercial-scale manufacturing facility expansion; offset by decreases in expenses associated with the pivotal Phase 3 clinical trial, which completed patient enrollment in January 2006. Total stock-based compensation included in research and development was approximately $670,000 and $1.7 million for the three and nine months ended September 30, 2007, respectively, compared to approximately $458,000 and $1.4 million for t
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Hill-Rom Holdings, Inc. ... to a management presentation at the Morgan Stanley Global ... EDT. You are invited to listen to ... http://ir.hill-rom.com/events.cfm or access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP ... available one hour after conclusion of the live event ...
(Date:8/27/2014)... An experimental drug designed to help regulate the blood,s iron ... of inflammation, according to results from the first human ... Blood , the Journal of the American ... a condition that occurs when red blood cells are in ... has anemia, the body does not get enough oxygen, since ...
(Date:8/27/2014)... , Aug. 27, 2014 ... research report is available in its ... for Application and Approval of Imported ... Practices (2014 Edition) ... Now, Chinese regulations on medical ...
Breaking Medicine Technology:Drug Represents First Potential Treatment for Common Anemia 2Drug Represents First Potential Treatment for Common Anemia 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10
(Date:8/27/2014)... Houston, TX (PRWEB) August 27, 2014 ... The reality is that depression has a mortality ... those with bi-polar disorder is slightly less, though it's ... of roughly 7%. In order to properly treat ... schizophrenia, and bi-polar, medication must be taken as directed. ...
(Date:8/27/2014)... Illinois (PRWEB) August 27, 2014 Aspirus ... project in the US with Buzz™ Digital O.R. at ... foundation of all 13 new operating rooms will be ... and management. This integrative system supports planning, navigation, imaging ... an advanced fusion of intuitive software and hardware all ...
(Date:8/27/2014)... of the leading purveyors of real and synthetic hair wigs, hair ... its products, for the coming Labor Day. , People searching for ... hair products in two ways: when they spend more than $89 ... LABOR10; while when they spend more than $299, they can save ... code is needed when securely checkout, there are about 50 products ...
(Date:8/27/2014)... is the second leading cause of cancer-associated death ... the difficulty in treating this cancer using conventional ... etoposide or combinations therein. This may be attributed ... to reach in a sufficient concentration in the ... harmful to the rest of the body. Considering ...
(Date:8/27/2014)... which repel water and oil and are persistent ... processing. These characteristics have made the fluorochemicals useful ... for food paper and board. , The problem ... break down and accumulate in both humans and ... harmful health effects, such as cancer, increased cholesterol ...
Breaking Medicine News(10 mins):Health News:MedicationDiscountCard.com now Makes Brintellix and Mental Illness Medications More Affordable with Discount Cards 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:UniWigs Is Offering A Big Sale for Labor Day on All Its Products 2Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 2Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 3Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 3
... new findings don,t apply to men , , MONDAY, Aug. ... against skin cancer and may actually boost the risk, ... study. , "Taking into consideration our results, we are ... in sun-seekers and people wanting to look tanned [using ...
... A patients expectations about the side effects of ... other side effects. Worries about severe allergic reactions to ... recent study from the Lineberger Comprehensive Cancer Center at ... Vanderbilt-Ingram Comprehensive Cancer Center and the Sarah Canon Cancer ...
... researchers say , , MONDAY, Aug. 20 (HealthDay News) -- ... C. Hurlbert wondered why all the products aimed at her ... professor of visual neuroscience at Newcastle University in England, Hurlbert ... whether girls really do prefer pink. The answer, as outlined ...
... Findings probably apply to males of other ethnicities, researchers say ... increases the risk of stroke in Chinese men, a new ... were 40 and older and had no history of stroke ... the men was conducted between 1999 and 2000, researchers found ...
... 20, 2007 - Lissamine green sounds like the latest ... something you would want to get in your eyes. ... staining patterns that are key to diagnosing dry eye ... for treating the potentially sight-stealing disease, new research at ...
... between brain cells along hairlike extensions called axons. For ... just transmit information they can turn the signal ... finding may help scientists develop treatments for psychiatric disorders ... thought that different parts of the brain do not ...
Cached Medicine News:Health News:Antioxidant Supplements May Raise Women's Skin Cancer Risk 2Health News:Antioxidant Supplements May Raise Women's Skin Cancer Risk 3Health News:Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US 2Health News:Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US 3Health News:Girls Really Do Prefer Pink 2Health News:Heavy Drinking Boosts Stroke Risk for Chinese Men 2Health News:Eye-staining technique offers early detection for dry eye syndrome 2Health News:Eye-staining technique offers early detection for dry eye syndrome 3Health News:Brain cells work differently than previously thought 2
For the quantitative determination of Gamma Glutamyltransferase in serum or plasma...
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
The XCHO method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of cholesterol in serum and plasma....
For the quantitative in vitro determination of Cholesterol in serum and plasma....
Medicine Products: